US artificial intelligence company Anthropic has acquired drug developer Mithril Medicine, bringing an early muscular dystrophy program in-house and testing whether one scientist, supported by its [···]

Adjunctive pharmaceutical cannabidiol has the most consistent comparative evidence for reducing seizure frequency in selected drug-resistant epilepsy. Evidence for refractory pain and multiple [···]

Management of drug-resistant bacterial pneumonia has become increasingly precise, but early precision does not remove the need to reinterpret the patient's course during illness. Active and [···]

Oral GLP-1 drugs can require 10 to 100 times more peptide than injections because of poor absorption, increasing manufacturing, purification and supply demands for weight-loss treatments.

...

Tennesseans deserve access to reliable, safe, and affordable treatment options.

Learn how the CDC weighs treatment options, spread, and future infections to assess drug-resistant germs — and why death tolls tell only part of the story.

Oct 28 (Reuters) - Oura said on Wednesday it has launched a clinical trial to study how sleep, heart rate and other measures monitored by the company's smart ring are associated with outcomes of [···]

Mindfulness-Oriented Recovery Enhancement (MORE), a behavioral therapy used alongside medication treatment, may help people with opioid use disorder respond differently to drug-related cues and [···]

The FDA has granted orphan drug designation to OCT-980, an oral treatment being developed for rhodopsin-associated autosomal dominant retinitis pigmentosa, according to a press release from Octant [···]

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner. The post New idiopathic pulmonary fibrosis [···]

contributor Dr. Alok Patel explains the report and what people can do for treatment and prevention.

Geron said on Wednesday it would halt a late-stage trial of its blood cancer treatment, marking a setback for the company's only commercial product, sending its shares... Reuters Health Information

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage [···]